The "Invitation" on March 14-15, 2024, Haibu Pharmaceutical invites you to gather in Hangzhou for the [National Pharmaceutical R&D and Investment Merger and Acquisition Cooperation Conference].

Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as "Haibu Pharmaceutical") was established in 2005 and is a high-tech enterprise with "chemical drug research and development" as its core capability. It has a research and development center in Beijing, a pilot verification center for raw materials and formulations, and a GMP industrial production base, mainly engaged in CRO services for raw materials and formulations, MAH joint licensing, related applications for raw materials, and commercial supply of pharmaceutical intermediates.It has rich experience in the research and production transfer, registration application, etc., of various dosage forms such as chemical raw materials, oral solids, liquid preparations, sterile injections, and external preparations. The R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular and cerebrovascular diseases, digestive system disorders, respiratory system issues, etc.

Haibu Pharmaceutical has been awarded the title of "Top 20 Pharmaceutical R&D Companies in China" for several consecutive years and has been recognized as a "Specialized and Innovative" enterprise in Beijing, a "National High-tech Enterprise", a "Beijing Science and Technology Research Development Institution", and a "Beijing Yizhuang Enterprise Innovation Center", among others.